Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort

Immune-checkpoint inhibitors (ICIs) have emerged relatively recently as a new therapeutic option for advanced non-small –cell lung cancer (NSCLC): as second-line therapy after chemotherapy [1], first-line monotherapy for patients with>50% programed cell-death –protein-1 ligand-1 (PD-L1) expression on tumor cells [2] or in combination with chemotherapy for any PD-L1–expression level [3]. However, ICIs can cause immune-related adverse events (irAEs) affecting any organ but, most frequently, skin, colon, endocrine organs, liver and lungs [4].

Source: Lung Cancer - March 16, 2020 Category: Cancer & Oncology Authors: Mateo Sanchis-Borja, Charles Ricordel, Anne Marie Chiappa, Jos é Hureaux, Luc Odier, Gaelle Jeannin, Renaud Descourt, Radj Gervais, Isabelle Monnet, Jean-Bernard Auliac, Christos Chouaïd Source Type: research